Technical Analysis for ATNX - Athenex, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 4.315 | -3.68% | -0.17 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Historical ATNX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Down 10% | 2 days ago | |
| 60 Minute Opening Range Breakdown | 2 days ago | |
| 2x Volume Pace | 2 days ago | |
| Down 5% | 2 days ago | |
| Fell Below Previous Day's Low | 2 days ago |
Get this analysis on your stocks daily!
- Earnings date: 11/05/2020
Athenex, Inc. Description
Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancers Oncology Organic Compounds Chemotherapy Radiation Antineoplastic Drugs Organic Chemistry Dermatitis Therapies For Cancer Nausea Vomiting Docetaxel Pruritus Scars Treatment Of Various Types Of Cancers
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 15.24 |
| 52 Week Low | 3.9701 |
| Average Volume | 2,559,450 |
| 200-Day Moving Average | 12.07 |
| 50-Day Moving Average | 11.61 |
| 20-Day Moving Average | 10.91 |
| 10-Day Moving Average | 8.44 |
| Average True Range | 1.00 |
| ADX | 35.87 |
| +DI | 8.25 |
| -DI | 54.52 |
| Chandelier Exit (Long, 3 ATRs ) | 12.00 |
| Chandelier Exit (Short, 3 ATRs ) | 6.97 |
| Upper Bollinger Band | 18.05 |
| Lower Bollinger Band | 3.77 |
| Percent B (%b) | 0.04 |
| BandWidth | 130.95 |
| MACD Line | -2.03 |
| MACD Signal Line | -1.05 |
| MACD Histogram | -0.9786 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.12 | ||||
| Resistance 3 (R3) | 5.10 | 4.80 | 4.99 | ||
| Resistance 2 (R2) | 4.80 | 4.60 | 4.81 | 4.94 | |
| Resistance 1 (R1) | 4.56 | 4.47 | 4.41 | 4.58 | 4.90 |
| Pivot Point | 4.26 | 4.26 | 4.19 | 4.28 | 4.26 |
| Support 1 (S1) | 4.02 | 4.06 | 3.87 | 4.05 | 3.73 |
| Support 2 (S2) | 3.73 | 3.93 | 3.74 | 3.69 | |
| Support 3 (S3) | 3.48 | 3.73 | 3.64 | ||
| Support 4 (S4) | 3.51 |
